,user_input,reference_contexts,reference,persona_name,query_style,query_length,synthesizer_name
0,Can you explain what the trial involving Sym004 in Combination with FOLFIRI is about and what it aims to achieve in patients with metastatic colorectal cancer?,"[""CLINICAL TRIAL PROTOCOL\nTrial Title:\nAn Open-label, Multi-Center Phase 1b/2a Trial Investigating Different Doses of Sym004 in Combination with FOLFIRI in Patients with Metastatic Colorectal Cancer Progressing after First-Line Therapy\nShort Title:\nSym004 in Combination with FOLFIRI in Metastatic Colorectal Cancer Patients\nSponsor:\nSymphogen A/S\nSponsor's Medical Expert:\nCoordinating Investigator:\nTrial ID:\nSym004-09\nTrial Phase:\nPhase 1b/2a\nEudraCT number:\n2015-003047-19\nIND Number:\n105953\nProtocol Version/Date:\n4.0 / 22-Feb-2017 (Amendment 3)\nPrevious Protocol Versions/Dates:\n3.0 / 05-Aug-2016 (Amendment 2)\n2.0 / 09-Nov-2015 (Amendment 1)\n1.0 / 26-Aug-2015\nList of Responsible Person/ Contact Listing\nLists of Investigators responsible for conducting the trial, medically qualified physicians responsible for all trial site related medical decisions (if other than the Investigators), Monitors, clinical laboratories and other medical and/or\ntechnical departments and/or institutions involved in the trial are provided as separate documents.""]","The trial titled 'An Open-label, Multi-Center Phase 1b/2a Trial Investigating Different Doses of Sym004 in Combination with FOLFIRI in Patients with Metastatic Colorectal Cancer Progressing after First-Line Therapy' aims to evaluate the effectiveness of Sym004 when used alongside FOLFIRI in patients who have metastatic colorectal cancer that has progressed after initial treatment. This trial is sponsored by Symphogen A/S and is in Phase 1b/2a, indicating it is in the early stages of testing the drug combination for safety and efficacy.",Experienced Doctor,POOR_GRAMMAR,LONG,single_hop_specific_query_synthesizer
1,Wut iz the significance of a confedential documnt in a clinical trial protocol?,"['CLINICAL TRIAL PROTOCOL\nGCP Statement: The trial will be conducted in compliance with this Clinical Trial Protocol, ICH E6 GCP (1) and applicable regulations.\nThis confidential document is the property of Symphogen A/S. No unpublished information contained herein may be passed on, reproduced, published or used without prior written approval from Symphogen A/S. Access to this document must be restricted to relevant parties.']","The confidential document is significant as it is the property of Symphogen A/S and contains unpublished information that cannot be passed on, reproduced, published, or used without prior written approval from Symphogen A/S. Access to this document must be restricted to relevant parties, ensuring the integrity and confidentiality of the trial.",Experienced Doctor,MISSPELLED,LONG,single_hop_specific_query_synthesizer
2,What does the approval of the Clinical Trial Protocol by the sponsor indicate?,['Sponsor\nI hereby approve the Clinical Trial Protocol as suitable and appropriate for use.\nSymphogen A/S\nSymphogen A/S\nSymphogen A/S\nSymphogen A/S'],The approval of the Clinical Trial Protocol by the sponsor indicates that it is deemed suitable and appropriate for use.,Young Nurse,PERFECT_GRAMMAR,MEDIUM,single_hop_specific_query_synthesizer
3,What is the role of the investigational product in the clinical trial according to the signature page?,"[""Signature Page Principal Investigator\nI, the undersigned, am responsible for the conduct of the trial at this site and agree;\n- \uf0b7 To assume responsibility for the proper conduct of the clinical trial at this Investigational Site\n- \uf0b7 Not to implement any changes to the Clinical Trial Protocol without agreement from the Sponsor and prior review and written approval from the Ethics Committee, except where necessary to eliminate an immediate hazard to the patient\n- \uf0b7 That I am aware of, and will comply with 'Good Clinical Practice' (ICH GCP) (CPMP/ICH/135/95) and all applicable regulatory requirements\n- \uf0b7 That all site staff to which I have delegated tasks for this clinical trial, are adequately informed about the investigational product(s) and of their trial-related duties and functions as described in the Clinical Trial Protocol\n________________________________\n____________________\nSignature\nDate of Signature\nName:\nAcademic degree:\nFunction:\nInstitution:""]","The investigational product is crucial as it must be adequately understood by all site staff to whom tasks have been delegated for the clinical trial, as described in the Clinical Trial Protocol.",Young Nurse,MISSPELLED,LONG,single_hop_specific_query_synthesizer
4,Can you elaborate on the significance of the section titled 'BACKGROUND AND RATIONALE' as indicated in the table of contents?,"['TABLE OF CONTENTS\n1, 1 = LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS......................... 1, 2 = 11. 2, 1 = SYNOPSIS.............................................................................................................. 2, 2 = 14. 3, 1 = BACKGROUND AND RATIONALE................................................................... 3, 2 = 19. 3.1, 1 = Disease']","The section titled 'BACKGROUND AND RATIONALE' is crucial as it provides the foundational context and justification for the study or discussion that follows. It typically outlines the reasons for the research, the existing knowledge on the topic, and the gaps that the current work aims to address.",Experienced Doctor,PERFECT_GRAMMAR,LONG,single_hop_specific_query_synthesizer
5,Wht is the current tretment for metastatic colorectal cancer?,"['TABLE OF CONTENTS\nand Treatment ............................................................................................ 3.1, 2 = 19. 3.1.1, 1 = Metastatic Colorectal Cancer .................................................................................. 3.1.1, 2 = 19. 3.1.2, 1 = Current Treatment of Metastatic Colorectal Cancer']","The current treatment of metastatic colorectal cancer is detailed in the context provided, specifically under section 3.1.2.",Experienced Doctor,MISSPELLED,LONG,single_hop_specific_query_synthesizer
6,What is the definition of disease?,"['TABLE OF CONTENTS\nDisease.................................. 3.1.2, 2 = 19. 3.2, 1 = Investigational Medicinal Product .......................................................................... 3.2, 2 = 19. 3.2.1, 1 =']","The context does not provide a specific definition of disease, but it indicates that disease is a topic listed in the table of contents.",Experienced Doctor,PERFECT_GRAMMAR,SHORT,single_hop_specific_query_synthesizer
7,Can you provide detailed information about the Mechanism of Action as referenced in the context of Sym004?,"['TABLE OF CONTENTS\nSym004.................................................................................................................... 3.2.1, 2 = 19. 3.2.2, 1 = Mechanism of Action.............................................................................................. 3.2.2, 2 = 20. 3.2.3, 1 =']","The context indicates that the Mechanism of Action is a specific section referenced in the table of contents for Sym004, but it does not provide detailed information about it. The section is listed under 3.2.2, indicating that further details may be found in that specific part of the document.",Experienced Doctor,WEB_SEARCH_LIKE,LONG,single_hop_specific_query_synthesizer
8,What section follows the Summary of Non-clinical Findings?,"['TABLE OF CONTENTS\nSummary of Non-clinical Findings......................................................................... 3.2.3, 2 = 20. 3.2.4, 1 = Summary of Clinical Findings ................................................................................ 3.2.4, 2 = 20. 3.2.4.1, 1 =']",The section that follows the Summary of Non-clinical Findings is the Summary of Clinical Findings.,Experienced Doctor,PERFECT_GRAMMAR,SHORT,single_hop_specific_query_synthesizer
9,What pharmacokinetics mean in medicine?,"['TABLE OF CONTENTS\nSafety....................................................................................................................... 3.2.4.1, 2 = 20. 3.2.4.2, 1 = Pharmacokinetics ....................................................................................................']","Pharmacokinetics is a term used in medicine that refers to the movement of drugs within the body, including how they are absorbed, distributed, metabolized, and excreted.",Experienced Doctor,POOR_GRAMMAR,MEDIUM,single_hop_specific_query_synthesizer
10,What is the EudraCT number for the clinical trial protocol?,"[""CLINICAL TRIAL PROTOCOL\nTrial Title:\nAn Open-label, Multi-Center Phase 1b/2a Trial Investigating Different Doses of Sym004 in Combination with FOLFIRI in Patients with Metastatic Colorectal Cancer Progressing after First-Line Therapy\nShort Title:\nSym004 in Combination with FOLFIRI in Metastatic Colorectal Cancer Patients\nSponsor:\nSymphogen A/S\nSponsor's Medical Expert:\nCoordinating Investigator:\nTrial ID:\nSym004-09\nTrial Phase:\nPhase 1b/2a\nEudraCT number:\n2015-003047-19\nIND Number:\n105953\nProtocol Version/Date:\n4.0 / 22-Feb-2017 (Amendment 3)\nPrevious Protocol Versions/Dates:\n3.0 / 05-Aug-2016 (Amendment 2)\n2.0 / 09-Nov-2015 (Amendment 1)\n1.0 / 26-Aug-2015\nList of Responsible Person/ Contact Listing\nLists of Investigators responsible for conducting the trial, medically qualified physicians responsible for all trial site related medical decisions (if other than the Investigators), Monitors, clinical laboratories and other medical and/or\ntechnical departments and/or institutions involved in the trial are provided as separate documents.""]",The EudraCT number for the clinical trial protocol is 2015-003047-19.,Young Nurse,WEB_SEARCH_LIKE,SHORT,single_hop_specific_query_synthesizer
11,What is the GCP statement in the clinical trial protocol?,"['CLINICAL TRIAL PROTOCOL\nGCP Statement: The trial will be conducted in compliance with this Clinical Trial Protocol, ICH E6 GCP (1) and applicable regulations.\nThis confidential document is the property of Symphogen A/S. No unpublished information contained herein may be passed on, reproduced, published or used without prior written approval from Symphogen A/S. Access to this document must be restricted to relevant parties.']","The GCP statement indicates that the trial will be conducted in compliance with the Clinical Trial Protocol, ICH E6 GCP, and applicable regulations.",Young Nurse,MISSPELLED,LONG,single_hop_specific_query_synthesizer
12,What is the role of Symphogen A/S in the clinical trial protocol?,['Sponsor\nI hereby approve the Clinical Trial Protocol as suitable and appropriate for use.\nSymphogen A/S\nSymphogen A/S\nSymphogen A/S\nSymphogen A/S'],Symphogen A/S is identified as the sponsor that approves the Clinical Trial Protocol as suitable and appropriate for use.,Young Nurse,PERFECT_GRAMMAR,MEDIUM,single_hop_specific_query_synthesizer
13,Wut is the current treatmnt for Metastatic Colorectal Cancer?,"['TABLE OF CONTENTS\nand Treatment ............................................................................................ 3.1, 2 = 19. 3.1.1, 1 = Metastatic Colorectal Cancer .................................................................................. 3.1.1, 2 = 19. 3.1.2, 1 = Current Treatment of Metastatic Colorectal Cancer']","The current treatment of Metastatic Colorectal Cancer is detailed in the context provided, specifically in section 3.1.2.",Experienced Doctor,MISSPELLED,LONG,single_hop_specific_query_synthesizer
14,"Can you provide detailed information about the trial identified as Sym004-09, including its schedule of events and version?","['TABLE OF CONTENTS\n5.3, Trial ID: Sym004-09 = Schedule of Events.................................................................................................. 5.3, Version 4.0 = 31. 5.3.1, Trial ID: Sym004-09 =']",The trial identified as Sym004-09 includes a schedule of events as outlined in the table of contents. It is associated with Version 4.0.,Young Nurse,PERFECT_GRAMMAR,LONG,single_hop_specific_query_synthesizer
15,What does the term 'Treatment' refer to in the context of the trial ID Sym004-09?,"['TABLE OF CONTENTS\n4.0 = 33. 5.3.3, Trial ID: Sym004-09 = Treatment ................................................................................................................ 5.3.3, Version 4.0 = 33. 5.3.4, Trial ID: Sym004-09 = End of Treatment and One Month Follow-up Visit ................................................ 5.3.4, Version 4.0 = 34. 5.3.5, Trial ID: Sym004-09 = Flow Chart']","In the context of trial ID Sym004-09, 'Treatment' refers to the section outlined in the table of contents, specifically related to the procedures and protocols followed during the trial.",Young Nurse,PERFECT_GRAMMAR,MEDIUM,single_hop_specific_query_synthesizer
16,What is the Trial ID for Sym004-09?,"['TABLE OF CONTENTS\nPatients.................................................................................................. 5.5, Version 4.0 = 37. 5.6, Trial ID: Sym004-09 = End of Trial ............................................................................................................. 5.6, Version 4.0 = 37. 5.7, Trial']",The Trial ID for Sym004-09 is mentioned as 'End of Trial' in the context provided.,Experienced Doctor,WEB_SEARCH_LIKE,SHORT,single_hop_specific_query_synthesizer
17,What does Version 4.0 refer to in the context of the document?,"['TABLE OF CONTENTS\nID: Sym004-09 = Independent Evaluation Committees. 5.7, Version 4.0 = ..................................................................... 37. 6, Trial ID: Sym004-09 = PATIENT SELECTION AND WITHDRAWAL................................................... 6, Version 4.0 = 38. 6.1, Trial ID: Sym004-09 = Inclusion Criteria All']","Version 4.0 refers to specific sections in the document, including Independent Evaluation Committees and patient selection and withdrawal criteria.",Young Nurse,WEB_SEARCH_LIKE,MEDIUM,single_hop_specific_query_synthesizer
18,What is FOLFIRI and how is it related to treatment in the context of the trial ID Sym004-09?,"['TABLE OF CONTENTS\nTreatment........................................................................... 6.3, Version 4.0 = 41. 6.3.1, Trial ID: Sym004-09 = Withdrawal from Treatment with Sym004 and/or FOLFIRI.................................. 6.3.1, Version 4.0 = 42. 6.3.2, Trial ID: Sym004-09 = Withdrawal from Trial']",FOLFIRI is mentioned in the context of withdrawal from treatment with Sym004 and/or FOLFIRI in the trial ID Sym004-09.,Young Nurse,MISSPELLED,LONG,single_hop_specific_query_synthesizer
19,What information is available regarding the trial ID Sym004-09 in the context of dose-expansion phases?,"['TABLE OF CONTENTS\n4.0 = ........................................................................................... 43. 6.4.2, Trial ID: Sym004-09 = Dose-Expansion Phase............................................................................................ 6.4.2, Version 4.0 = 43. 7, Trial ID: Sym004-09 =']","The trial ID Sym004-09 is associated with the dose-expansion phase, as indicated in section 6.4.2 of the provided context.",Young Nurse,WEB_SEARCH_LIKE,LONG,single_hop_specific_query_synthesizer
